WO2009130198A3 - Hyperglycosylated human coagulation factor ix - Google Patents

Hyperglycosylated human coagulation factor ix Download PDF

Info

Publication number
WO2009130198A3
WO2009130198A3 PCT/EP2009/054707 EP2009054707W WO2009130198A3 WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3 EP 2009054707 W EP2009054707 W EP 2009054707W WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3
Authority
WO
WIPO (PCT)
Prior art keywords
coagulation factor
human coagulation
polypeptides
hyperglycosylated human
hyperglycosylated
Prior art date
Application number
PCT/EP2009/054707
Other languages
French (fr)
Other versions
WO2009130198A2 (en
Inventor
Gert Bolt
Claus Kristensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP2011505482A priority Critical patent/JP5665733B2/en
Priority to US12/937,331 priority patent/US20110137011A1/en
Priority to EP09734022A priority patent/EP2268807A2/en
Priority to CN2009801244941A priority patent/CN102105582A/en
Publication of WO2009130198A2 publication Critical patent/WO2009130198A2/en
Publication of WO2009130198A3 publication Critical patent/WO2009130198A3/en
Priority to US13/723,576 priority patent/US8871714B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Abstract

The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
PCT/EP2009/054707 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix WO2009130198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2011505482A JP5665733B2 (en) 2008-04-21 2009-04-21 Highly glycosylated human coagulation factor IX
US12/937,331 US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
EP09734022A EP2268807A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
CN2009801244941A CN102105582A (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor IX
US13/723,576 US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103629 2008-04-21
EP08103629.5 2008-04-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/937,331 A-371-Of-International US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
US13/723,576 Continuation US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Publications (2)

Publication Number Publication Date
WO2009130198A2 WO2009130198A2 (en) 2009-10-29
WO2009130198A3 true WO2009130198A3 (en) 2010-05-06

Family

ID=41217185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054707 WO2009130198A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix

Country Status (5)

Country Link
US (2) US20110137011A1 (en)
EP (3) EP2268807A2 (en)
JP (2) JP5665733B2 (en)
CN (1) CN102105582A (en)
WO (1) WO2009130198A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
EP2209487A4 (en) * 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
US9249405B2 (en) 2008-09-15 2016-02-02 Paolo Simioni Factor IX polypeptide mutant, its uses and a method for its production
CN103140237A (en) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 Factor ix polypeptides and methods of use thereof
PL2625262T3 (en) * 2010-10-05 2016-05-31 Novo Nordisk Healthcare Ag Process for protein production
TWI557135B (en) 2010-11-03 2016-11-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EA028914B1 (en) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Assays to monitor bleeding disorders
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
EP2877202A4 (en) 2012-07-25 2016-06-01 Biogen Ma Inc Blood factor monitoring assay and uses thereof
BR112015001628A2 (en) * 2012-07-25 2017-11-07 Catalyst Biosciences Inc modified factor x polypeptides and their use
PT3366705T (en) * 2012-09-12 2023-07-19 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
EP2900328A4 (en) 2012-09-25 2016-05-11 Biogen Ma Inc Methods of using fix polypeptides
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
JP2016513666A (en) * 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド Tissue metalloproteinase inhibitor type 3 (TIMP-3) variants, compositions and methods
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015044418A1 (en) * 2013-09-30 2015-04-02 Crucell Holland B.V. Method for the clarification of high density crude cell culture harvest
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
JP2017500017A (en) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
SG10201808158UA (en) 2014-03-19 2018-10-30 Genzyme Corp Site-specific glycoengineering of targeting moieties
JP7058940B2 (en) 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド Freeze-dried factor IX preparation
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2017011336A1 (en) 2015-07-10 2017-01-19 E.&J. Gallo Winery System and method for dispensing a beverage
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
DK3411478T3 (en) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
CN111247251A (en) 2017-08-09 2020-06-05 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
KR20200057051A (en) 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. Methods, compositions and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
AU2020258483A1 (en) 2019-04-17 2021-11-11 Evox Therapeutics, Ltd. Compositions of exosomes and AAV
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107278B1 (en) * 1982-08-04 1989-11-15 National Research Development Corporation Molecular cloning of the gene for human anti-haemophilic factor ix
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
ES2327606T3 (en) * 2000-01-10 2009-11-02 Maxygen Holdings Ltd CONJUGATES OF G-CSF.
DE60138364D1 (en) * 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20070026485A1 (en) * 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
ES2346072T3 (en) 2004-08-17 2010-10-08 Csl Behring Gmbh DEPENDENT MODIFIED POLYPEPTIDES OF VITAMIN K.
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIMURO J ET AL: "Specific detection of human coagulation factor IX in cynomolgus macaques", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 2, no. 2, 1 February 2004 (2004-02-01), pages 275 - 280, XP009125189, ISSN: 1538-7933, [retrieved on 20040107] *

Also Published As

Publication number Publication date
US20130095555A1 (en) 2013-04-18
JP2011517954A (en) 2011-06-23
US8871714B2 (en) 2014-10-28
CN102105582A (en) 2011-06-22
WO2009130198A2 (en) 2009-10-29
US20110137011A1 (en) 2011-06-09
EP2444491B1 (en) 2016-11-16
EP2268807A2 (en) 2011-01-05
EP2444491A2 (en) 2012-04-25
EP2444491A3 (en) 2012-08-08
EP2811017A2 (en) 2014-12-10
JP2015038075A (en) 2015-02-26
JP5665733B2 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
HK1146485A1 (en)
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
IL209121A (en) Indazolyl derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of inflammatory diseases
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
IL178939A (en) Dual and triple combinations suitable for the synergistic treatment of breast cancer, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments or as medicaments for the treatment of breast cancer
MY150931A (en) Substituted oxazolidinones and their use
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2012000954A (en) Pharmaceutical compositions.
WO2009053628A3 (en) Novel compounds, preparation and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124494.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734022

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009734022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011505482

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12937331

Country of ref document: US